Vold, M.D., Ph.D., discusses the current treatment landscape for progressive pulmonary fibrosis, highlighting nonpharmacological and pharmacological options to manage the disease.

Centene Corporation’s Ambetter Health Solutions names Alan Silver as the first president of Individual Coverage Health ...

Employer purchasers have largely been on the sidelines when it comes to policy proposals that target high healthcare prices.

A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare ...

The move means the pulmonary arterial hypertension drug is now available in the United States, Europe, and the United Kingdom ...

Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.

In a review of previous studies, researchers found that the images seen on social media contribute to taking actions that are both beneficial with patients seeking dermatological care and unfavorable ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...